Research Funded

Abstract: The CIC-DUX4 fusion oncoprotein is an understudied molecular entity that characterizes a rare but lethal subset of undifferentiated round cell sarcomas. CIC-DUX4 patients have dismal clinical outcomes due to 1) an incomple... Read More

Abstract: Advances in pediatric oncology have occurred for some cancers, however, new therapies for sarcoma (osteosarcoma and rhabdomyosarcoma) have been sparse. The 5-year disease-free survival is 20-30% for patients with metastati... Read More

Abstract: Synovial sarcoma is a deadly form of malignant soft tissue tumors, most commonly affecting children and young adults. Approximately all the patients bear a pathognomonic chromosomal translocation, t(X;18), which fuses the ... Read More

Abstract: Malignant sarcomas comprise 12% of all pediatric cancers. Despite its rare occurrence, sarcomas are life threatening and difficult to treat, and nearly half of all patients will have recurrence and metastasis.  The two mo... Read More

Abstract: Angiosarcoma (AS) is an aggressive disease that accounts for 2-3% of soft tissue sarcomas (STS). The long-term outlook of patients with incurable advanced or metastatic disease is poor, with a median overall survival of le... Read More

Abstract: Liposarcomas (LPSs) are heterogenous group of soft-tissue sarcomas, which outcome depends strongly on the site of the primary tumor and tumor histotype. At the moment, there are not available any efficacious targeted thera... Read More

Abstract: Amongst pediatric cancers, bone and soft tissue sarcomas are often associated with the poorest prognoses and most limited effective treatment options. Understanding the genetics that predispose to the development of childh... Read More

Abstract: Ewing sarcoma is the second common bone cancer in children and young adults. It is an aggressive type of cancer that spreads rapidly to other organs in the body. Ewing sarcoma that recurs or that has spread to other parts ... Read More

Abstract: Ewing sarcoma (ES) is the second most pediatric common bone cancer (1,2). While patients with localized disease have a five-year survival rate of ~75%, this plummets to 20% for metastatic and recurrent disease. Immunothera... Read More

Abstract: Antigen presentation is a universal process in which proteins in a cell are degraded into small fragments (peptides) and displayed on the cell surface for interrogation by the immune system. If a peptide is derived from an... Read More

Abstract: PEGylated Arginine Deiminase (ADI-PEG20) is a therapeutic that degrades extracellular arginine.  In tumors like sarcoma that cannot make their own arginine due to a urea cycle defect, this agent put tumors into a starvati... Read More

Abstract: Osteosarcoma is the most common childhood malignancy, with a sharp decline in survival rates upon metastasis. We have previously demonstrated administration of immune checkpoint blockade (ICB) of anti-CTLA-4/anti-PD-L1 to ... Read More

Abstract: Leiomyosarcoma is the most common type of uterine sarcoma (uLMS), with an annual incidence of slightly less than two women per 100,000, characterized by a very poor response to standard therapies and an aggressive clinical... Read More

Abstract:  Liposarcoma is one of the most common soft-tissue sarcomas, with well-differentiated/dedifferentiated liposarcoma subtype forming the majority of cases. Although recurrences are frequent, surgery remains the mainstay of ... Read More

Abstract: Gastrointestinal stromal tumor (GIST), the most common sarcoma, results from oncogenic mutations that usually occur in the KIT genes. Though anti-KIT tyrosine kinase inhibitors (TKIs) can be initially effective, half of pa... Read More